Introduction {#s1}
============

Estrogen and progesterone are the main players in mammary development and the progression of breast cancers ([@bib20]; [@bib32]). Both hormones act through their cognate receptors, estrogen receptor (ER) and progesterone receptor (PR) ([@bib20]). The mechanisms of ERα activity have been extensively studied ([@bib7]). However, the upstream regulation of ERα (*Esr1*) expression is much less understood.

The mammary gland is an epithelial organ profoundly influenced by estrogen and progesterone. The mammary gland is composed of basal and luminal cells, which can be separated by surface expression of CD24 and CD29/CD49f ([@bib41]; [@bib45]). ER^+^ or PR^+^ cells, consisting 30 \~ 50% of luminal cells, can be enriched by surface expression of Sca1 ([@bib37]; [@bib42]; [@bib44]). Hormones exert their mitogenic effects primarily through induction of local growth factors ([@bib1]; [@bib3]; [@bib4]; [@bib25]; [@bib36]).

R-spondin1 (Rspo1) has been identified as a hormone-mediated local factor, whose expression is upregulated by estrogen and progesterone ([@bib5]; [@bib4]). R-spondin protein family (Rspo1-4) have been reported to function as niche factors for adult stem cells in multiple organs ([@bib17]; [@bib18]; [@bib35]; [@bib43]), and Rspo1 has been implicated as critical growth factor in many in vitro stem cell expansion systems, including intestine, stomach and liver ([@bib2]; [@bib24]; [@bib27]; [@bib40]). The role of Rspo1 in Wnt signaling has been extensively studied. Rspo1, through its interaction with its receptors Lgr4/5/6, enhances Wnt signaling by attenuating the turnover of Wnt receptors ([@bib19]; [@bib28]) and potentiating phosphorylation of the Wnt co-receptor Lrp ([@bib6]; [@bib13]; [@bib15]; [@bib16]). In the mammary gland, Rspo1 synergizes with another niche factor, Wnt4, to promote mammary basal stem cell self-renewal ([@bib4]). In line with the role of Rspo1 in MaSC regulation, Rspo1 expression is enhanced in the diestrus phase of the estrous cycle and during pregnancy ([@bib4]), coinciding with the rise of progesterone level and the expansion of basal stem cells ([@bib1]; [@bib25]). Our recent study also reported the enhanced Rspo1 expression in estrus, a stage with high estrogen signaling activity ([@bib5]). Another role of Rspo1 may exist besides maintaining basal stem cells.

In this study, we uncover a novel function of Rspo1 distinct from its previously reported role in stem cell regulation. We provide evidence that Rspo1 promotes ERα (*Esr1*) expression in luminal cells of the mammary gland. This action of Rspo1 is through activating G-protein coupled cAMP/PKA pathway, while independent of Wnt/β-catenin signaling. Our data reveal a novel Wnt-independent role of Rspo1, and a new upstream regulatory axis for *Esr1* expression.

Results {#s2}
=======

Rspo1 induces ERα expression and promotes ERα signaling {#s2-1}
-------------------------------------------------------

To investigate the potential role of Rspo1 in luminal cells, we isolated primary luminal cells (Lin^-^, CD24^+^, CD29^lo^) by FACS (fluorescence-activated cell sorting), and cultured them in 3D Matrigel in the presence of RSPO1 (0.5 μg/ml) ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}). Transcriptome and Gene ontology (GO) analysis identified enrichment of various features, including estrogen receptor activity ([Figure 1a and b](#fig1){ref-type="fig"}). qPCR analysis verified that the expression of ERα signaling target genes, including *Pgr* (progesterone receptor, PR), *Ctsd1* (Cathepsin D1) ([@bib34]), *and Wisp2* ([@bib50]) are enhanced in the presence of RSPO1 ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}).

![Rspo1 enhances Esr1 transcription and ERα signaling activities.\
(**a**) RNA-seq of 3D cultured luminal cells in the presence of RSPO1 (0.5 μg/ml) or vehicle. Increased expression of ERα target genes (*Pgr*, *Greb1*) and *Esr1* were enlisted in heatmap of differentially expressed genes (DEGs). (**b**) GO analysis was conducted on upregulated genes and estrogen receptor activity was enhanced in the presence of RSPO1. (**c**) Sca1^+^ luminal cells were FACS-isolated. (**d, e**) qPCR analysis of cultured cells in day two indicating increased expression of *Esr1* (**e**) and its target genes (**d**) in the presence of RSPO1 (0.5 μg/ml). (**f**) E2 (1 μM) treatment was used as positive control indicating the upregulation of *Esr1* and its target *Pgr*. (**g**) Western analysis of cultured cells in day 2 showing increased ERα protein levels after RSPO1 treatment. (**h**) A luciferase reporter driven by the ESR1 promoter was constructed and transfected into HEK293T cells. RSPO1 treatment activated the *ESR1* promoter-luciferase reporter activities in a dose dependent manner. (**d--h**) Data are presented as mean ± s.e.m. of three independent experiments. Student's t test: \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05.](elife-56434-fig1){#fig1}

To further investigate how Rspo1 regulates ERα signaling, we isolated ER^+^ luminal cells (Lin^-^, CD24^+^, CD29^lo^, Sca1^+^) and ER^-^ luminal cells (Lin^-^, CD24^+^, CD29^lo^, Sca1^-^) based on Sca1 expression ([Figure 1c](#fig1){ref-type="fig"}), and cultured them in 3D. RSPO1 treatment resulted in the upregulation of ERα targets, *Pgr*, *Ctsd1* and *Wisp2* in ER^+^ luminal cells, indicating the further activation of ERα signaling ([Figure 1d](#fig1){ref-type="fig"}). Interestingly, the expression of ERα itself (*Esr1*) is also enhanced ([Figure 1e](#fig1){ref-type="fig"}). In contrast, ER^-^ luminal cells did not respond to RSPO1 stimulation ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}). Estrogen (Estradiol-E2, E2) is one of the few known upstream regulator of *Esr1* ([@bib12]; [@bib26]). Thus, E2 (1 μM) was used as control to show the extent of *Esr1* activation. We found that in this ER^+^ luminal cell culture system, RSPO1 elevated the expression of *Esr1* and its target *Pgr* to a level comparable with E2 treatment (compare [Figure 1d--e](#fig1){ref-type="fig"} with [Figure 1f](#fig1){ref-type="fig"}). The upregulation of ERα protein by RSPO1 was confirmed by Western blot analysis ([Figure 1g](#fig1){ref-type="fig"}). This role of RSPO1 was further validated in mouse mammary Eph4 cells. RSPO1 upregulates the expression of *Esr1* and ERα signaling targets *Pgr* and *Greb1* (growth regulation by estrogen in breast cancer 1) in a dose-depending manner ([Figure 1---figure supplement 2a--c](#fig1s2){ref-type="fig"}).

To investigate whether Rspo1 regulates *Esr1* transcription, we utilized a luciferase reporter driven by the proximal promoter (promoter A) of human *ESR1* ([@bib46]). We found that RSPO1 can induce luciferase expression in a dose-dependent manner, while the control reporter lacking *ESR1* promoter was not activated in any conditions ([Figure 1h](#fig1){ref-type="fig"}). Together, these data suggest that Rspo1 enhances *Esr1* transcription.

Rspo1-induced ERα expression is dependent on Lgr4 {#s2-2}
-------------------------------------------------

To investigate the mechanisms through which Rspo1 regulates *Esr1*, we first examined which receptor of Rspo1 is involved. qPCR analysis indicated that all three Lgr receptors, Lgr4/5/6 are expressed in basal cells, but only Lgr4 is expressed in luminal cells ([Figure 2a](#fig2){ref-type="fig"}), suggesting that Rspo1 may rely on Lgr4 to signal in luminal cells in the context of *Esr1* induction. Within the luminal compartment, Lgr4 was evenly distributed in ER^+^ (Sca1^+^) and ER^-^ (Sca1^-^) luminal cells ([Figure 2a](#fig2){ref-type="fig"}). In situ hybridization validated the expression pattern of *Lgr4* in both basal and luminal layers ([Figure 2b](#fig2){ref-type="fig"}). We next investigated whether Lgr4 mediates Rspo1's action on *Esr1* expression. We generated Lgr4 shRNA and validated its knockdown efficacy in primary luminal cells by qPCR analysis ([Figure 2c](#fig2){ref-type="fig"}). Lgr4 knockdown suppressed the upregulation of *Esr1* induced by RSPO1 ([Figure 2d](#fig2){ref-type="fig"}). In an *ESR1-*luciferase reporter assay using T47D (a human breast cancer cell line), LGR4 knockdown also inhibited the luciferase activities induced by RSPO1 ([Figure 2e](#fig2){ref-type="fig"}). The effect was validated using two different shRNAs ([Figure 2e](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Results suggest that Rspo1 relies on Lgr4 to activate *Esr1* expression.

![Rspo1 inducing *Esr1* expression is dependent on Lgr4.\
(**a**) qPCR analysis of Lgrs in FACS-isolated basal and luminal cells. *Lgr4*, *Lgr5* and *Lgr6* are all expressed in basal cells, while only *Lgr4* is distinctively expressed in luminal cells with even distribution in Sca1^+^ (ER^+^) and Sca1^-^ (ER^-^) luminal subpopulations. (**b**) Lgr4 in situ hybridization (in pink) confirming its expression in basal (arrow) and luminal cells (arrowhead). Nuclei were counterstained with hematoxylin (in purple). Scale bar, 20 μm. (**c**) qPCR analysis of *Lgr4* expression in cultured luminal cells indicating successful knockdown by shRNA. (**d**) qPCR analysis of *Esr1* expression in cultured luminal cells indicating that knockdown of *Lgr4* by shRNA counteracts the upregulation of *Esr1* by RSPO1. (**e**) *ESR1* promoter-luciferase reporter assays on T47D cells indicating that knockdown of LGR4 mRNA by shRNA counteracts the upregulation of *ESR1* by RSPO1, while scramble shRNA cannot. Data in (**c--f**) are pooled from three independent experiments and are presented as mean ± s.e.m. Student's t test: \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05; ns, not significant.](elife-56434-fig2){#fig2}

ERα induction by Rspo1 is independent of Wnt/β-catenin signaling {#s2-3}
----------------------------------------------------------------

As Rspo1 is known for amplifying Wnt/β-catenin signaling, we investigated whether Wnt ligands have a synergistic influence on *Esr1* expression. We first examined Wnt4, a major Wnt ligand in the mammary gland that can activate Wnt/β-catenin signaling ([@bib4]; [@bib36]). The activation of *Axin2* expression indicated that Wnt/β-catenin signaling was activated in primary luminal cell culture in the presence of Wnt4 ([Figure 3a](#fig3){ref-type="fig"}). Wnt4+RSPO1 combination further stimulated *Axin2* expression ([Figure 3a](#fig3){ref-type="fig"}). Intriguingly, addition of Wnt4 alone was ineffective in activating *Esr1* expression in these cells ([Figure 3b](#fig3){ref-type="fig"}), and Wnt4+RSPO1 combination was unable to further increase *Esr1* level compared to RSPO1 alone ([Figure 3b](#fig3){ref-type="fig"}). These results suggest that canonical Wnt signaling may not be involved in this regulatory axis. Furthermore, we used either Wnt3a or a GSK3 inhibitor CHIR99021 (CHIR) to stimulate Wnt/β-catenin signaling in primary luminal cell culture. Although Wnt-signaling activators markedly increased the expression levels of its target gene *Axin2* ([Figure 3c](#fig3){ref-type="fig"}), they could not stimulate *Esr1* expression ([Figure 3d](#fig3){ref-type="fig"}). It is noteworthy that the combination of RSPO1 with CHIR did not further induce *Axin2* level ([Figure 3c](#fig3){ref-type="fig"}), probably due to the Wnt/β-catenin signaling activity induced by CHIR or Wnt3a had reached plateau. In contrast to their stimulating effect to *Axin2*, Wnt3a and CHIR treatment suppressed *Esr1* expression ([Figure 3d](#fig3){ref-type="fig"}), an observation in line with a previous report, in which Wnt/β-catenin signaling represses the expression of luminal differentiation genes, mainly *Esr1* ([@bib30]). Inhibition of the Frizzled receptor using its soluble CRD domain (FzCRD) ([@bib22]) or stimulating β-catenin degradation using XAV939 ([@bib23]) effectively suppressed *Axin2* expression induced by Wnt3a ([Figure 3c](#fig3){ref-type="fig"}), still, they could not suppress *Esr1* upregulation by Rspo1 ([Figure 3d](#fig3){ref-type="fig"}). To further verify, we used HEK293T cells transiently expressing *ESR1*-luciferase reporter and cultured them in the presence of RSPO1 or RSPO1 in combination with XAV939 or IWP2. Consistently, inhibition of WNT signaling did not affect *ESR1* promoter activities induced by RSPO1 ([Figure 3e and f](#fig3){ref-type="fig"}). Together, these data suggest that Rspo1 induces ERα expression independent of Wnt/β-catenin signaling.

![*Esr1* expression induced by Rspo1 is independent of Wnt/β-catenin signaling.\
(**a--b**) qPCR analysis of cultured luminal cells indicating that Wnt4 alone or in combination with RSPO1 can activate Wnt target *Axin2* expression (**a**). While RSPO1 alone promoted *Esr1* expression, Wnt4 was ineffective for *Esr1*. Combination of RSPO1 and Wnt4 displayed no difference compared with RSPO1 alone (**b**). (**c--d**) qPCR analysis of cultured luminal cells indicating that Wnt signaling activators (Wnt3a and GSK3β inhibitor CHIR) cannot activate *Esr1* expression, and that *Esr1* expression induced by RSPO1 cannot be suppressed by addition of Wnt signaling inhibitor (FzCRD or β-catenin inhibitor XAV939) (**d**). In contrast, Wnt-target gene *Axin2* expression was activated in the presence of Wnt signaling activators, and was suppressed by adding the signaling inhibitors (**c**). (**e--f**) HEK293T cells with transiently expressing *ESR1*-luciferase reporter were cultured in the presence of RSPO1, or in combination with Wnt inhibitors (XAV939 and IWP2). Wnt inhibitors cannot suppress *ESR1*-luciferase activities induced by RSPO1. Data in (**a--f**) are pooled from more than three independent experiments and presented as mean ± s.e.m. Student's t test. \*\*\*\*p\<0.0001, \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05; ns, not significant.](elife-56434-fig3){#fig3}

Loss of luminal Rspo1 results in decreased ERα expression in vivo {#s2-4}
-----------------------------------------------------------------

To investigate the role of Rspo1 in vivo, we generated a conditional *Rspo1* knockout allele in which the second *Rspo1* exon is subjected to removal upon *Cre* recombination, resulting in frame-shift of the remaining exons ([Figure 4a](#fig4){ref-type="fig"}, also see [Figure 4---figure supplement 1a--b](#fig4s1){ref-type="fig"}). Of note, *Rspo1* is predominantly expressed in ER- luminal cells as described previously ([@bib4]), while *Esr1* is expressed in ER^+^ luminal cells. Thus, this Rspo1-*Esr1* regulation is likely achieved through a paracrine manner in vivo. A luminal cells-specific BAC transgenic CreER line, *Keratin8-CreER* (*Krt8-CreER*) ([@bib49]), was used to generate luminal cells-specific *Rspo1* knock-out mice (*Krt8-CreER;Rspo1^fl/fl^*) (Rspo1-cKO) ([Figure 4b](#fig4){ref-type="fig"}). Tamoxifen was administered into 8-week-old nulliparous female mice, and mammary glands were examined 4 weeks later. Whole-mount carmine staining showed significantly reduced side branches in Rspo1-cKO mice when compared with the control (*Rspo1^fl/fl^*) ([Figure 4c and d](#fig4){ref-type="fig"}). These results are consistent with previous observation in a *Rspo1^-/-^* mammary transplantation model ([@bib10]). The knockout efficacy of Rspo1-cKO was validated. ER^-^ luminal cells (Lin^-^, CD24^+^, CD29^lo^, Sca1^-^), where Rspo1 is expressed, were isolated ([Figure 4e](#fig4){ref-type="fig"}). *Rspo1* level in cKO group was significantly reduced shown by qPCR analysis ([Figure 4f](#fig4){ref-type="fig"}). By whole-mount immunofluorescence staining, we observed the decreased ERα expression in *Rspo1-cKO* mammary gland ([Figure 4g](#fig4){ref-type="fig"}). Quantification indicated decreased percentage of ERα^+^ cells ([Figure 4h](#fig4){ref-type="fig"}), likely reflecting the overall reduction of ERα level in luminal compartment. Although we could not exclude the possible switching of ER^+^ to ER^-^ cell fate due to other indirectly reasons, we tested a more direct possibility---whether it is the reduction of ERα expression in ER+ compartment that results in loss of ER^+^ cells. To this end, we isolated ER+ luminal cells (Lin^-^, CD24^+^, CD29^lo^, Sca1^+^), and analyzed ERα levels as well as ERα signaling activities. We found that ERα levels were reduced in this compartment as shown by qPCR ([Figure 4i](#fig4){ref-type="fig"}) and Western analysis ([Figure 4j](#fig4){ref-type="fig"}). Consistently, ERα signaling target genes, including *Pgr*, *Wisp2* and *Ctsd1* were declined in *Rspo1-cKO* group ([Figure 4k](#fig4){ref-type="fig"}). Therefore, together these results suggest that loss of Rspo1 results in reduced ERα expression and its signaling activities in luminal cells.

![Loss of Rspo1 in mammary luminal cells results in reduced side branching and decreased ERα expression.\
(**a**) Schematic illustration of *Rspo1^flox^* knock-in allele generation (see also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). (**b**) *Krt8-CreER;Rspo1^fl/fl^* inducible model specifically knockdown Rspo1 in luminal cells. (**c--d**) 8-week-old adult virgin mice were Tamoxifen injected twice, 1 day apart (2 mg/25 g body weight per injection). Mammary glands were obtained 4 weeks later. Whole-mount imaging (**c**) of mammary epithelium and quantification (**d**) showing decreased side branches in Rspo1-cKO mice. n = 3. Scale bar, 2 mm. More than six views were used for quantification. (**e--f**) FACS gating strategy for mammary basal and luminal cell isolation. Luminal ER^+^ and ER^-^ subpopulations were separated based on Sca1 (**e**). qPCR analyses of luminal cells showing efficient Rspo1 knockdown in *Krt8-CreER;Rspo1^fl/fl^* (**f**). (**g--h**) Immunostaining indicated decreased ERα^+^ cell number after Rspo1 knockdown (**g**). Scale bar, 40 μm. Quantification of ERα^+^ cells were performed in (**h**). (**i**) qPCR analyses of ER^+^ luminal cells indicated downregulation of *Esr1* transcription after Rspo1 knockdown in ER^-^ cells. (**j**) Sca1^+^ (ER^+^) luminal cells were FACS isolated and Western blot was performed to indicate decreased ERα expression after Rspo1 knockdown. (**k**) qPCR analyses of ER^+^ luminal cells indicated downregulation of ERα target genes after Rspo1 knockdown in ER^-^ cells. Data are presented as mean ± s.e.m. of more than three independent experiments. Student's t test: \*\*\*\*p\<0.0001, \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05. L.N. Lymph node.](elife-56434-fig4){#fig4}

The *Esr1* expression was also examined in *Lgr4^lacZ^* mouse model, a hypomorphic allele of Lgr4, ([@bib33]). Mammary glands of Lgr4 homozygous mutant (*Lgr4^lacZ/lacZ^*) were isolated for whole mount imaging. At 9 weeks, *Lgr4^lacZ/lacZ^* mammary glands displayed significantly less side branches ([Figure 4---figure supplement 2a--b](#fig4s2){ref-type="fig"}). Immunostaining revealed decreased ERα expression in *Lgr4^lacZ/lacZ^* mammary gland ([Figure 4---figure supplement 2c--d](#fig4s2){ref-type="fig"}). When ER^+^ luminal cells (Lin^-^, CD24^+^, CD29^lo^, Sca1^+^) were isolated, we found that *Esr1* was significantly reduced in *Lgr4* mutant, so were the ERα downstream targets *Pgr*, *Ctsd1* and *Wisp2* ([Figure 4---figure supplement 2e](#fig4s2){ref-type="fig"}). *Lgr4* expression was markedly decreased in *Lgr4^lacZ/lacZ^* mammary gland as a validation of the hypomorphic nature of the allele ([Figure 4---figure supplement 2e](#fig4s2){ref-type="fig"}). These results support that Lgr4 plays a role in mediating Rspo1-induced ERα expression.

Genetic evidence supports that *Esr1* regulation is independent of luminal Wnt4 {#s2-5}
-------------------------------------------------------------------------------

To investigate whether Wnt/β-catenin signaling affects *Esr1* in vivo, we also generated a Wnt4 conditional knockout mouse. In this model, the second *Wnt4* exon is flanked by flox, and is removed upon *Cre* recombination, which leads to frame shift of the remaining exons ([Figure 5a](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1a--b](#fig5s1){ref-type="fig"}). We generated inducible, luminal cells-specific *Wnt4* knock-out mice (*Krt8-CreER;Wnt4^fl/fl^*) ([Figure 5b](#fig5){ref-type="fig"}). Tamoxifen was administered into 8-week-old nulliparous female mice, and mammary glands were examined 4 weeks later. Loss of Wnt4 resulted in reduced side branching ([Figure 5c and d](#fig5){ref-type="fig"}), consistent with a previous report using *MMTV-Cre;Wnt4^fl/fl^* model ([@bib36]).

![Loss of Wnt4 increases *Esr1* expression in luminal cells.\
(**a**) Schematic illustration of *Wnt4^flox^* knock-in allele generation (see also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). (**b**) *Krt8-CreER;Wnt4^flox^* inducible model specifically knockdown Wnt4 in luminal cells. (**c--d**) 8-week-old adult virgin mice were Tamoxifen administered for 2 courses at 1 day apart, 2 mg/25 g body weight per injection and harvested 4 weeks later. Whole-mount imaging of the mammary epithelium showing decreased side branches in *Wnt4*-cKO mice (**c**). n = 3. Scale bar, 1 mm. More than six views were used for quantification. (**e**) qPCR of isolated ER^+^ luminal cells validated efficient Wnt4 knockdown in cKO mice. (**f**) qPCR analysis of ER^+^ luminal cells indicated Wnt4 loss increased *Esr1* expression levels. (**g**) Western blot analysis indicated increased ERα protein level in *Wnt4*-cKO. (**h**) qPCR analysis of ER^+^ luminal cells indicated increased ERα signaling pathway activity after Wnt4 knockdown. (**i**) qPCR analysis of basal cells showed Wnt signaling pathway was decreased after Wnt4 knockdown. Data are presented as mean ± s.e.m. Student's t test: \*\*\*\*p\<0.0001, \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05; ns, not significant.](elife-56434-fig5){#fig5}

To address whether loss of Wnt4 affects *Esr1*, we isolated ER^+^ luminal populations from both *Wnt4*-cKO (*Krt8-CreER;Wnt4^fl/fl^*) and control (*Krt8-CreER;Wnt4^fl/+^*) mammary gland. qPCR and Western analyses both indicated that loss of Wnt4 increases ERα level in ER^+^ luminal cells ([Figure 5f--g](#fig5){ref-type="fig"}), as well as ERα signaling activities showed by increased target gene expression ([Figure 5h](#fig5){ref-type="fig"}). These were in contrast to the reduced *Esr1* level and ERα signaling activity observed in Rspo1-cKO mice ([Figure 4i--k](#fig4){ref-type="fig"}). These were consistent with the in vitro results that Wnt3a and CHIR treatment suppressed *Esr1* expression ([Figure 3d](#fig3){ref-type="fig"}), and consistent with the previous report, in which Wnt-controlled transcriptional regulator LBH repress luminal genes, mainly *Esr1* ([@bib30]). The successful deletion of Wnt4 in cKO group was validated by significantly reduced *Wnt4* level in ER^+^ luminal cells ([Figure 5e](#fig5){ref-type="fig"}), as well as reduced expression of Wnt/β-catenin signaling targets *Axin2* and *Lgr5* in basal cells ([Figure 5i](#fig5){ref-type="fig"}). Together, in vivo genetic evidence supports that *Esr1* regulation is independent of luminal Wnt4.

Rspo1 relies on cAMP-PKA pathway to induce *Esr1* expression {#s2-6}
------------------------------------------------------------

To further investigate the downstream mechanisms through which Rspo1/Lgr4 regulate *Esr1*, we conducted an inhibitor-based screen. HEK293T cells with transiently expressing *ESR1*-luciferase reporter were cultured in the presence of RSPO1, and screened for molecules that could suppress luciferase activity using a GPCR inhibitor library ([Figure 6a](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). Amongst over 250 inhibitors, the cAMP inhibitor Bupivacaine HCl (Bup), effectively suppressed *ESR1*-luciferase activities induced by RSPO1 ([Figure 6a](#fig6){ref-type="fig"}). Considering that the major downstream effector of cAMP in mammalian cells is Protein Kinase A (PKA), we examined the effect of inhibition of PKA. Consistently, H89, an inhibitor of PKA effectively repressed *ESR1*-luciferase activities induced by RSPO1 ([Figure 6a](#fig6){ref-type="fig"}). The inhibitory effects of Bup and H89 were further examined in primary luminal cell culture. Both inhibitors suppressed *Esr1* expression stimulated by Rspo1 as shown by qPCR ([Figure 6b](#fig6){ref-type="fig"}), but were ineffective on *Axin2* expression ([Figure 6c](#fig6){ref-type="fig"}). Considering the cAMP-PKA pathway can also be activated by estrogen and ERα ([@bib9]), we further examined whether *Esr1* induction by RSPO1 involves ERα. We found that the ERα inhibitor ICI (ICI182, 780) does not affect *ESR1* promoter activities that are induced by RSPO1 ([Figure 6d](#fig6){ref-type="fig"}), suggesting that *Esr1*-induction by Rspo1 does not involve ERα.

![Rspo1 inducing *Esr1* expression relies on cAMP-PKA pathway.\
(**a**) HEK293T cells transfected with *ESR1*-luciferase reporter were cultured in the presence of RSPO1, and in combination with pharmaceutical compounds from a GPCR inhibitor library (Selleck). Bupivacaine HCl (Bup), a cAMP inhibitor, and H89, a PKA inhibitor, suppressed *Esr1*-luciferase activities induced by RSPO1 (see [Figure 6---figure supplement 1a--b](#fig6s1){ref-type="fig"}). (**b--c**) qPCR analysis of cultured luminal cells indicating both Bup and H89 counteracted the upregulation of *Esr1* expression induced by RSPO1 (**b**), while *Axin2* expression is not affected (**c**). (**d**) HEK293T cells with transiently expressing *ESR1*-luciferase reporter were cultured in the presence of RSPO1 alone or with ERα inhibitor ICI182, 780. Luciferase activities were measured. ICI did not affect the *ESR1* upregulation induced by RSPO1. (**e**) CRE site on *ESR1* promoter-luciferase reporter was mutated, and RSPO1 could not activate the reporter with CRE mutation. (**f**) RSPO1-FL, RSPO1-R66A/Q71A mutant could, but RSPO1-N137Q and RSPO1-F110A/F106A mutants could not induce *Esr1* promoter luciferase activities. (**g**) ΔLuminescence was read out after Eph4 cells were treated with forskolin (FSR) or RSPO1 for 30 min, ΔLuminescence was calculated as Luminescencetreated---Luminescenceuntreated. Rspo1 treatment induced cAMP production in Eph4 cells in a dose dependent manner. (**h**) Illustration of Rspo1 regulated Esr1 expression mediated by cAMP-PKA pathway. Data in (**a--d**) are pooled from three independent experiments and presented as mean ± s.e.m. Student's t test: \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05; ns, not significant.\
Figure 6---source data 1.ESR1-luciferase activities induced by RSPO1 in combination with a GPCR inhibitor library.](elife-56434-fig6){#fig6}

The transcription factor CREB (cAMP response element binding protein) is the best-characterized nuclear protein that mediates stimulation of transcription by cAMP. CREB binds to the conserved consensus cAMP response element (CRE, sequence TGACATCA) ([@bib39]). A CRE was found at the proximal promoter of *ESR1* (−991 to −984 bp). Therefore, we examined whether this CRE is responsible for induction of *ESR1* by RSPO1. While RSPO1 induced the wild type promoter-luciferase in a dose-dependent manner, it could not activate the reporter with CRE mutations (TGcCAgCA) ([Figure 6e](#fig6){ref-type="fig"}), rendering its specificity. In addition, we co-expressed *ESR1*-luciferase with RSPO1-FL (full length), RSPO1-N137Q (a mutated form with compromising secretion) ([@bib11]), RSPO1 F110A/F106A (unable to bind LGR4) ([@bib47]), and RSPO1 R66A/Q71A (binds to LGRs but is unable to amplify Wnt signaling) ([@bib48]). RSPO1-FL and RSPO1 R66A/Q71A were able to activate the luciferase activities, but RSPO1-N137Q and RSPO1 F110A/F106A could not ([Figure 6f](#fig6){ref-type="fig"}), suggesting the secretion of Rspo1 and its association to LGR4 are critical for *Esr1* transcription. This is in line with the paracrine mechanism we propose. Next, we attempted to directly measure the change of cAMP level upon Rspo1 treatment in mammary Eph4 cells, using Forskolin (FSR) as a positive control. We observed a dose dependent increase of cAMP level in relation to increasing RSPO1 stimulation ([Figure 6g](#fig6){ref-type="fig"}). Together, these results suggest that Rspo1 signals through cAMP-PKA-CREB axis to promote *Esr1* transcription (illustrated in [Figure 6h](#fig6){ref-type="fig"}).

Discussion {#s3}
==========

In this study, we uncover a novel function and signaling mechanism of Rspo1 in promoting ERα expression. This action of Rspo1 is dependent on Lgr4 and G-protein coupled cAMP/PKA pathway, but independent of Wnt/β-catenin signaling. In vivo, the biological significance of this regulatory axis is first revealed in the mammary gland homeostasis. Luminal cells-specific deletion of Rspo1 results decreased ERα expression and reduced side branching.

A novel Wnt-independent role of Rspo1 {#s3-1}
-------------------------------------

Rspo1 has been known as a stem cell growth factor in many adult tissues with prominent biological and therapeutic significance. The action of Rspo1 on stem cells is through strongly potentiating Wnt signaling ([@bib6]; [@bib13]; [@bib15]; [@bib16]; [@bib19]; [@bib28]). Here we unveil a new role of Rspo1 in promoting *Esr1* transcription in hormone receptor-positive luminal cells. This Wnt/β-catenin-independent action of Rspo1 relies on the Lgr4 receptor and intracellular cAMP/PKA signaling. Knockdown of Lgr4 counteracts Rspo1's augmenting effect on ERα transcription in vitro and in vivo, while modulation of Wnt input or β-catenin activity does not affect *Esr1* level induced by Rspo1. Same holds true in vivo when using Wnt4-cKO mouse model. Deletion of *Wnt4* in luminal cells increased *Esr1* level. To our best knowledge, this is the first report of Wnt/β-catenin independent function of Rspo1 in physiological condition. It adds to previous reported Wnt/β-catenin independent role of Rspo1 in antagonizing colon cancer metastasis, in which LGR5 directly binds to TGFβ receptors for the activation of TGFβ signaling ([@bib51]).

Rspo1 activates G-protein coupled cAMP signaling in regulating *Esr1* {#s3-2}
---------------------------------------------------------------------

cAMP is a well-known intracellular mediator of protein hormones including FSH (follicle-stimulating hormone), LH (luteinizing hormone), and TSH (thyroid stimulating hormone), which bind to LGR1, LGR2 and LGR3 respectively ([@bib14]). These known hormone receptors belong to the class-A LGRs. Class-B LGRs, including LRG4-6, are reported to promote phosphorylation of Lrp5/6 and stabilization of β-catenin without the G-protein-coupled cAMP production ([@bib6]; [@bib13]). There have been a few reports that suggest differently, in that Lgr4 activates cAMP/PKA signaling in bone ([@bib31]), and in the male reproductive system ([@bib29]). Independently, our data demonstrate that Rspo1/Lgr4 relies on the cAMP/PKA axis to maintain proper *Esr1* expression during mammary development. This action is highly likely cell type specific. In vivo, either conditional KO of Rspo1 or Lgr4 hypomorphic mutant leads to reduced *Esr1* expression. The latter is in line with previous reports in the male reproductive system, in which deficiency of Lgr4 results in reduced *Esr1* in the efferent ducts and epididymis ([@bib21]; [@bib29]). The current study, for the first time, demonstrates that Rspo1 can activate cAMP/PKA signaling.

A new hormonal regulation feed forward mechanism {#s3-3}
------------------------------------------------

Our previous studies find that hormones indirectly activate Rspo1 expression in ER^-^ luminal cells ([@bib4]), and identify Areg (in ER^+^ cells) as the intermediate paracrine factor for the hormonal regulation of Rspo1 expression (in ER^-^ cells) ([@bib5]). Moreover, the elevated levels of Areg and Rspo1 are also detected in estrus, a stage with high estrogen signaling activity ([@bib5]). In this study, we found that Rspo1 in turn enhances ERα expression in ER^+^ cells. This may represent a feed forward mechanism engaging estrogen-ERα-Rspo1-ERα, highlighting the impact of local growth factors for the amplification of hormonal signaling output. This additional layer of ERα regulation by Rspo1 could be hijacked during tumor initiation or progression. Elucidating the molecular mechanisms on how estrogen engages with ERα in the mammary gland is the key for advancing current knowledge over breast cancer progression and resistance to hormone therapy.

In conclusion, our study demonstrated a novel Wnt-independent role of Rspo1, revealed a novel Rspo1-Lgr4-cAMP-ERα regulatory axis. As ERα is crucial for the development and diseases of various tissues, this new Rspo1 signaling axis may have broader implication in estrogen-associated diseases.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                                     Source or reference                                             Identifiers                                                          Additional\
  (species) or resource                                                                                                                                                                                                                  information
  --------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Genetic reagent (*M. musculus*)   *Krt8-CreERT2*                                                  PMID:[22350718](https://www.ncbi.nlm.nih.gov/pubmed/22350718)   RRID:[MGI:5314229](https://scicrunch.org/resolver/MGI:5314229)       Dr. Li Xin (Department of Molecular and Cellular Biology, Baylor College of Medicine, United States)

  Genetic reagent (*M. musculus*)   *Rspo1^flox/+^*                                                 This paper                                                                                                                           Generated in our laboratory Detail refer to [Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}

  Genetic reagent (*M. musculus*)   *Wnt4^flox/+^*                                                  This paper                                                                                                                           Generated in our laboratory Detail refer to [Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}

  Genetic reagent (*M. musculus*)   *Lgr4^LacZ/+^*                                                  PMID:[15192078](https://www.ncbi.nlm.nih.gov/pubmed/15192078)   RRID:[MGI:3052121](https://scicrunch.org/resolver/MGI:3052121)       Drs. Minyao Liu and Dali Li

  Cell line (*M. musculus*)         Eph4                                                            PMID:[25260709](https://pubmed.ncbi.nlm.nih.gov/25260709)                                                                            Mouse mammary epithelial cell line

  Cell line (*H. sapiens*)          HEK293T (293T)                                                  <http://www.cellbank.org.cn>                                    Cat. \#: SCSP-502                                                    

  Cell line (*H. sapiens*)          T47D                                                            Dr. Gaoxiang Ge\'s laboratory                                                                                                        Human breast cancer cell line\
                                                                                                                                                                                                                                         Dr. Gaoxiang Ge (Institute of Biochemistry and Cell Biology)

  Antibody                          Rabbit anti Gapdh GAPDH Polyclonal Antibody                     Proteintech                                                     Cat. \#: 10494--1-AP\                                                WB (1:3000)
                                                                                                                                                                    RRID:[AB_2263076](https://scicrunch.org/resolver/AB_2263076)         

  Antibody                          Mouse anti β-Actin Monoclonal Antibody                          Sigma                                                           Cat. \#: A2228\                                                      WB (1:2000)
                                                                                                                                                                    RRID:[AB_476697](https://scicrunch.org/resolver/AB_476697)           

  Antibody                          Rabbit anti ERα Polyclonal Antibody                             Millipore                                                       Cat. \#: 06--935\                                                    WB (1:1000), IHC (1:200)
                                                                                                                                                                    RRID:[AB_310305](https://scicrunch.org/resolver/AB_310305)           

  Antibody                          Rat anti Krt8 Monoclonal Antibody                               DSHB                                                            Cat. \#: TROMA-1                                                     IHC (1:500)

  Antibody                          Rat Anti-Mouse CD31 Monoclonal Antibody, Biotin Conjugated      BD PharMingen                                                   Cat. \#: 553371\                                                     Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_394817](https://scicrunch.org/resolver/AB_394817)           

  Antibody                          Rat Anti-Mouse CD45 Monoclonal Antibody, Biotin Conjugated      BD PharMingen                                                   Cat. \#: 553078\                                                     Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_394608](https://scicrunch.org/resolver/AB_394608)           

  Antibody                          Rat Anti-Mouse TER-119 Monoclonal Antibody, Biotin Conjugated   BD PharMingen                                                   Cat. \#: 553672                                                      Flow cytometry (1:200)

  Antibody                          Rat Anti-Mouse CD31 Monoclonal Antibody, FITC Conjugated        BD PharMingen                                                   Cat. \#: 553372\                                                     Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_394818](https://scicrunch.org/resolver/AB_394818)           

  Antibody                          Rat Anti-Mouse CD45 Monoclonal Antibody, FITC Conjugated        BD PharMingen                                                   Cat. \#: 553080\                                                     Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_394610](https://scicrunch.org/resolver/AB_394610)           

  Antibody                          Rat Anti-Mouse TER119 Monoclonal Antibody, FITC Conjugated      BD PharMingen                                                   Cat. \#: 557915                                                      Flow cytometry (1:200)

  Antibody                          PE/Cy7 Rat Anti-Mouse CD24 Monoclonal Antibody                  Biolegend                                                       Cat. \#: 101--822\                                                   Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_756048](https://scicrunch.org/resolver/AB_756048)           

  Antibody                          APC Armenian Hamster Anti-Mouse/Rat CD29 Monoclonal Antibody    Biolegend                                                       Cat. \#: 102216\                                                     Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_492833](https://scicrunch.org/resolver/AB_492833)           

  Antibody                          Rat Anti-Ly-6A/E (Sca-1) Monoclonal Antibody, PE                eBioscience                                                     Cat. \#: 12-5981-82\                                                 Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_466086](https://scicrunch.org/resolver/AB_466086)           

  Antibody                          Streptavidin eFluor 450 Conjugate                               eBioscience                                                     Cat. \#: 48-4317-82\                                                 Flow cytometry (1:200)
                                                                                                                                                                    RRID:[AB_10359737](https://scicrunch.org/resolver/AB_10359737)       

  Peptide, recombinant protein      Epithelial growth factor (EGF)                                  Corning                                                         Cat. \#: 354001                                                      50 ng/mL

  Peptide, recombinant protein      FzCRD                                                           PMID:[25260709](https://pubmed.ncbi.nlm.nih.gov/25260709/)                                                                           Inhibition of the Frizzled receptor using its soluble CRD domain. Purified in our laboratory (1:200)

  Peptide, recombinant protein      Wnt3A                                                           PMID:[20569694](https://www.ncbi.nlm.nih.gov/pubmed/20569694)                                                                        Purified in our laboratory 200 ng/ml

  Recombinant DNA reagent           plko.1 backbone                                                 Addgene                                                         RRID:[Addgene_30323](https://scicrunch.org/resolver/Addgene_30323)   

  Recombinant DNA reagent           pGL4.17 basic vector                                            Promega, Madison, WI, U.S.A.                                    Cat. \#: E6721                                                       

  Recombinant DNA reagent           pRL-TK Renilla                                                  Promega, Madison, WI, U.S.A.                                    Cat. \#: E2241                                                       

  Recombinant DNA reagent           pcDNA3.1-RSPO1 overexpression (RSPO1-OE) plasmid                This paper                                                                                                                           Constructed in our laboratoryDetail refer to Materials and methods

  Chemical compound, drug           tamoxifen (TAM)                                                 Sigma-Aldrich                                                   Cat. \#: T5648                                                       2 mg/20 g

  Chemical compound, drug           HEPES                                                           Sigma                                                           Cat. \#: H4034-500G                                                  25 mM

  Chemical compound, drug           Collagenase III                                                 Worthington                                                     Cat. \#: LS004183                                                    300 U/ml

  Chemical compound, drug           red blood cell lysing buffer                                    Sigma                                                           Cat. \#: R7757                                                       

  Chemical compound, drug           DNase I                                                         Sigma                                                           Cat. \#: D4263                                                       0.1 mg/mL

  Chemical compound, drug           Carmine                                                         Sigma                                                           Cat. \#: C1022                                                       2 mg/ml

  Chemical compound, drug           Histoclear                                                      National Diagnostics                                            Cat. \#: HS-200                                                      

  Chemical compound, drug           Matrigel                                                        BD Bioscience                                                   Cat. \#: 354230                                                      

  Chemical compound, drug           Insulin-Transferrin-Selenium (ITS)                              Gibco                                                           Cat. \#: 41400045                                                    Cell culture (1:100)

  Chemical compound, drug           E2                                                              Sigma                                                           Cat. \#: E8875                                                       1 μM

  Chemical compound, drug           IWP2                                                            Selleck                                                         Cat. \#: s7085                                                       2.5 μM

  Chemical compound, drug           CHIR                                                            Selleck                                                         Cat. \#: S1263                                                       3 μM

  Chemical compound, drug           XAV-939                                                         Selleck                                                         Cat. \#: S1180                                                       10 μM

  Chemical compound, drug           Protein A Agarose                                               Santa Cruz                                                      Cat. \#: sc-2003                                                     

  Chemical compound, drug           DAPI                                                            Life Technologies                                               Cat. \#: P36931                                                      

  Chemical compound, drug           GPCR compound library                                           Selleckchem L2200                                                                                                                    Chemical Biology Core Facility, Institute of Biochemistry and Cell Biology, SIBS, CAS

  Commercial assay or kit           In situ hybridization RNAscope kit                              Advanced Cell Diagnostics                                                                                                            Following the manufacturer's instructions

  Commercial assay or kit           Dual-Luciferase Reporter Assay System                           Promega                                                         Cat. \#: E1910                                                       Following the manufacturer's instructions

  Commercial assay or kit           cAMP-Glo assay kit                                              Promega                                                         Cat. \#: V1501                                                       Following the manufacturer's instructions

  Commercial assay or kit           SuperScript III kit                                             Invitrogen                                                      Cat. \#: RR036A                                                      Following the manufacturer's instructions

  Software, algorithm               GraphPad Prism                                                  GraphPad Prism (<https://graphpad.com>)                                                                                              

  Software, algorithm               ImageJ                                                          ImageJ (<http://imagej.nih.gov/ij/>)                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Experimental animals {#s4-1}
--------------------

*Rspo1^flox/+^* and *Wnt4^flox/+^* mice were constructed as illustrated in the text. In all conditional knockout experiments, mice were maintained on a C57BL/6 genetic background and at least three animals were analyzed for each genotype. *Lgr4^LacZ/+^*([@bib33]) and *Krt8-CreERT2* ([@bib49]) strains were used in this study. Nude, CD1 and BALB/c strains were purchased from B and K universal (Shanghai). Animals were housed under conditions of 12 h day/night cycle.

For Cre recombination induction experiments induced in adult mice, animals received intraperitoneal injection of 2 mg tamoxifen (TAM; Sigma-Aldrich; T5648) diluted in sunflower oil. The Animal Care and Use Committee of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences approved experimental procedures.

Antibodies {#s4-2}
----------

Rabbit anti Gapdh (1:3000; Proteintech; 10494--1-AP), Mouse anti β-Actin (1:2000; Sigma; A2228) and Rabbit anti ERα (1:1000; Millipore; 06--935) were used in Western blot analyses.

Primary cell preparation {#s4-3}
------------------------

Mammary glands from 8- to 12-wk-old virgin female mice were isolated. Minced tissues were placed in digestion buffer (RPMI 1640 \[Gibco; C11875500BT\] with 25 mM HEPES \[Sigma; H4034-500G\], 5% FBS \[Hyclone\], 1% PSQ \[Gibco; 15140122\], 300 U mL^-^1 Collagenase III \[Worthington; LS004183\]) and digested for 2 hr at 37°C. After lysis of the red blood cells in red blood cell lysing buffer (Sigma; R7757), a single cell suspension was obtained by sequential incubation with 0.05% Trypsin-EDTA (Gibco; 25300--062) for 5 min at 37°C and 0.1 mg/mL DNase I (Sigma; D4263) for 5 min with gentle pipetting followed by filtration through 70 µm cell strainers (Falcon; 352350).

RNA extraction and RNA sequencing {#s4-4}
---------------------------------

Total RNA from day two cultured luminal cells (Lin^-^, CD24+, CD29^lo^) were extracted with RNAiso Plus (Takara) following manufacturer's protocol. Total mRNA concentration was determined with NanoDrop ND-1000 and RNA-seq libraries were prepared according to manufacturer's instruction (Illumina) followed by applying to sequencing on Illumina nova-seq, which was performed by ANOROAD (<http://en.annoroad.com>, Beijing). Differential gene expression analysis was carried out and genes with significant alteration were extracted and further analysed using DAVID Bioinformatics Resources. RNA-seq data can be viewed online at <http://www.biosino.org/node/index>, under accession number OEP000754.

Mammary gland whole mount carmine staining {#s4-5}
------------------------------------------

The 4th pair of mammary glands were dissected and fixed for 2 hr in 4% paraformaldehyde, and then washed the tissue three times in PBS for 15 min each time. Finally, the tissues were stained in carmine alum solution (2 mg/ml carmine \[Sigma; C1022\], 5 mg/ml KAl(SO~4~)~2~ in H~2~O) overnight at room temperature. After the staining, the tissues were washed in de-staining solution (50% ethanol, 2% HCl) for 2 hr, and then serial dehydrated in 75%, 85%, 95%, 100%, 100% ethanol and finally stored in Histoclear (National Diagnostics; HS-200). Whole mount analyses were performed under a dissection microscope (Leica).

Mammary gland whole mount immunostaining {#s4-6}
----------------------------------------

Whole-mount staining was performed as previously described ([@bib38]), with minor modification. In brief, mammary glands were dissected into small pieces, then processed in digestion buffer (RPMI 1640 with 25 mM HEPES, 5% fetal bovine serum, 1% penicillin--streptomycin--glutamine (PSQ), 300 U/ml collagenase III (Worthington)) for 30 min at 37°C, then fixed in 4% paraformaldehyde for 30 min at 4°C. Tissues were incubated with primary antibodies (Krt8; 1:500; DSHB, ER; 1:200; Millipore) at 4°C overnight, followed by washes, incubated with secondary antibodies and DAPI (Life Technologies) at 4°C overnight. Then the tissues were incubated in 80% glycerol overnight, before dissection for 3D imaging. Confocal images were captured using Leica SP8 laser confocal scanning microscope. Representative images were shown in the figures.

Cell labeling and flow cytometry {#s4-7}
--------------------------------

The following antibodies in 1:200 dilutions were used: biotinylated and FITC conjugated CD31, CD45, and TER119 (BD PharMingen; 553371; 553078; 553672; 553372; 553080; 557915); CD24-PE/cy7, CD29-APC (Biolegend; 101--822; 102216) Sca1-PE and Streptavidin-V450 (eBioscience; 12-5981-82; 48-4317-82). Antibody incubation was performed on ice for 25 min in PBS with 5% FBS. All sorting experiments were performed using a FCAS Jazz (Becton Dickinson). The purity of sorted population was routinely checked and ensured to be \>95%.

In vitro culture assay {#s4-8}
----------------------

FACS-sorted cells were resuspended in chilled 100% growth factor-reduced Matrigel (BD Bioscience; 354230), and the mixture was allowed to polymerize before covering with culture medium (DMEM/F12 \[Gibco; 11039--021\]; ITS \[1:100; Gibco; 41400045\]; 50 ng mL^-^1 EGF \[Corning; 354001\]), plus either 1 μM E2 (Sigma; E8875), 200 ng Wnt3A, 1:100 FzCRD, 2.5 μM IWP2 (Selleck; s7085), 3 μM CHIR (Selleck; S1263), 10 μM XAV-939 (Selleck; S1180), Rspo1 purified protein or Wnt4 conditioned media. Culture medium was changed every 24 hr. Cell samples were collected after 2--4 days in culture for RT-qPCR and western blot.

Maintenance of cell lines {#s4-9}
-------------------------

293T and Eph4 cell lines were cultured in DMEM high glucose (4.5 g/L) (Gibco, C11995500BT) with 1% Penicillin/Streptomycin (Gibco, 15140) and 10% Fetal bovine serum (FBS) (Hyclone). Both cell lines were cultured in tissue culture dish, kept at 37°C with 5% CO~2~, trypsinized, and split three times a week 1:4. T47D cell line was kindly provided by Dr. Gaoxiang Ge, Institute of Biochemistry and Cell Biology and was cultured in 1640 Medium (Gibco, C11875500BT) +10 mg/ml Insulin with 1% Penicillin/Streptomycin and 10% FBS. All cell lines were routinely negatively tested for mycoplasma.

Conditioned media preparation {#s4-10}
-----------------------------

Wnt4 conditional medium was prepared by culturing Wnt4-expressing Eph4 cells for 48 hr, followed by supernatant collect. Wnt4 conditional medium was stored at 4°C for short-term storage (up to 1 week). For long-term usage, conditional medium was aliquoted after collection and stored at −80°C.

RSPO1 protein purification {#s4-11}
--------------------------

RSPO1-FC construct was cloned into expression vector with a C-terminal Fc tag. RSPO1-FC was transiently expressed in HEK293T cells and medium changed into CD293 medium (Gibco, 11913--019). One day after transfection, medium was collected by centrifugation and incubated with Protein A Agarose Beads (Santa Cruz, sc-2003). The bound recombinant protein was eluted using 500 μl 0.1M Glycine (pH = 3.0) and was collected in 1.5 ml tubes containing 30 ul 1 M Tris-HCl (pH = 9.5) buffer for neutralization. In total 5 tubes of elution were collected. The RSPO1 protein was subsequently purified and concentrated by Centrifugal Filter Volumes (Millipore, UFC803096).

Lentiviral vector and infection {#s4-12}
-------------------------------

Lgr4-shRNA was synthesized and subcloned into plko backbone with EGFP. Lentivirus was produced by transient transfection in 293 T cells. Mammary cells were isolated from 8- to 12-wk-old virgin female glands as described above, followed by sorting into luminal cells. The sorted cells were collected and cultured in a low adherent plate in EGF, ITS-supplemented DMEM/F12 with virus. At 12 hr after infection, cells were collected and resuspended in Matrigel for consequent in vitro culturing. Sequences of Lgr4-shRNA are CGTAATCAAATCTCCCTGATA and CCTCCAGAACAATCAGTTGAA.

Luciferase assay {#s4-13}
----------------

Oligonucleotide primers (nucleotides −1133 to −1107 and −1 to −24 based on previously published sequence information for the upstream region of the *ESR1* were used to generate *ESR1* promoter fragments from normal placental DNA by polymerase chain reaction (PCR) ([@bib8]). A 1133 bp (promoter A) of *ESR1* promoter expression vector (ERP) was created by cloning this PCR-generated product into the *XhoI-HindIII* sites of the promoterless luciferase reporter plasmid pGL4.17 basic respectively (Promega, Madison, WI, U.S.A.). Transfections of individual wells were performed using luciferase reporter plasmid (ERP or pGL4.17 basic vector alone), and pRL-TK Renilla luciferase control constructs as a correction for transfection efficiency, and also transfected with pcDNA3.1-RSPO1 overexpression (RSPO1-OE) plasmid (from 0.5 μg/ml to 4 μg/ml)) Cells were then harvested, the dual luciferase assays were performed using a commercial kit (Promega; E1910), Results are shown as fold activity over control activity of the promoterless pGL4.17 basic vector in each set of experiments. All transfections and assays were performed in duplicate with n ≥ 3 individual experiments. GPCR compound library (Selleckchem L2200) was used to for screening of inhibitors that suppress *ESR1* upregulation by RSPO1. In each experiment, *ESR1*-lucieferase reporter cells were treated with RSPO1 for 36--48 hr.

In situ hybridization {#s4-14}
---------------------

In situ hybridization was performed using the RNAscope kit (Advanced Cell Diagnostics) following the manufacturer's instructions. *Lgr4* probes were ordered from Advanced Cell Diagnostics. For in situ staining, at least three independent experiments were conducted. Representative images are shown in the figures.

AMP-Glo assay to detect intracellular cAMP levels {#s4-15}
-------------------------------------------------

The intracellular cAMP concentration was measured using the cAMP-Glo assay kit (Promega, V1501) according to the manufacturer's instruction. The cAMP standard curve was generated using purified cAMP, from which the relative intracellular level of cAMP was inferred. For each drug treatment, three biological repeats were used, and each experiment was repeated 2--3 times.

RT-qPCR {#s4-16}
-------

RNA was isolated with Trizol (Invitrogen; 9109). The cDNA library was prepared with the SuperScript III kit (Invitrogen; RR036A). RT--PCR was performed on a StepOne Plus (Applied Biosystems). RNA level was normalized to GAPDH. The primers used were as following:

1.  Axin2-F, AGCCTAAAGGTCTTATGTGGCTA;

2.  Axin2-R, ACCTACGTGATAAGGATTGACT;

3.  Wnt4-F, GCAATTGGCTGTACCTGG;

4.  Wnt4-R, GCACTGAGTCCATCACCT;

5.  Rspo1-F, GCAACCCCGACATGAACAAAT;

6.  Rspo1-R, GGTGCTGTTAGCGGCTGTAG;

7.  Esr1-F, TCCAGCAGTAACGAGAAAGGA

8.  Esr1-R, AGCCAGAGGCATAGTCATTGC

9.  Pgr-F, GGGGTGGAGGTCGTACAAG

10. Pgr-R, GCGAGTAGAATGACAGCTCCTT

11. Lgr4-F, AGAACTCAAAGTCCTAACCCTC

12. Lgr4-R, ATGCCGCAACTGAACGAG

13. Lgr5-F, CCTACTCGAAGACTTACCCAGT

14. Lgr5-R, GCATTGGGGTGAATGATAGCA

15. Lgr6-F, CTGTAGCCCTGGTGATGA

16. Lgr6-R, GGGTTGAAGAGCAGGTAG

17. Ctsd1-F, GCTTCCGGTCTTTGACAACCT

18. Ctsd1-R, CACCAAGCATTAGTTCTCCTCC

19. Wisp2-F, TGTGTGACCAGGCAGTGATG

20. Wisp2-R, GTGCTCCAGTTTGGACAGGG.

Statistical analysis {#s4-17}
--------------------

One-way ANOVA or Student's t-test was performed, and the P-value was calculated in Prism on data represented by bar charts, which consisted of results from three independent experiments unless otherwise specified. For all experiments with error bars, the standard deviation (SD) was calculated to indicate the variation within each experiment. No statistical method was used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

We are very excited to highlight your studies revealing a novel non-Wnt role for Rspo1 via cAMP-PKA activation. We believe that your studies will expand our understanding of how components of the Wnt pathway act through other non-related pathways.

**Decision letter after peer review:**

Thank you for submitting your article \"A novel function of R-spondin1 in regulating estrogen receptor expression independent of Wnt/β-catenin signaling\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Edward Morrisey as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Christof Niehrs (Reviewer \#1); Stijn De Langhe (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \'in revision at *eLife*\'. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

In particular, please pay attention to the comments by reviewer 1 and comments 1-3 by reviewer 2. While some of these will require additional data, others may be addressed be a careful editing of the conclusions made in the manuscript.

Reviewer \#1:

The manuscript by Geng et al., by the Zeng lab uncovers a new role of R-Spondin 1 (Rspo1) for estrogen receptor (*Esr1*) expression in mouse mammary gland. Rspo1 has been exclusively considered as a potent agonist in WNT signaling, where it plays a crucial role in stem cell maintenance and development. Geng and co-authors discovered an unexpected WNT-independent role of Rspo1 in cAMP-PKA signaling to regulate transcription of *Esr1*. The data support a paracrine mechanism involving an Rspo1-*Lgr4*-cAMP-PKA-*Esr1* axis between mammary gland ER+ and ER- cells.

Overall, this study is nicely designed and executed with a battery of biochemical analyses further supported by genetic evidence in mouse mutants. This study has broad significance for the mammary development, estrogen signaling, Rspo-Lgr, and Wnt signaling fields.

My only main point concerns the major finding that Rspo1 regulates the cAMP-PKA-*Esr1* axis via *Lgr4*. To better support this conclusion, the authors should provide some additional data:

1\) Figure 4H: For Rspo1 cKO, the authors show Pgr, *Wisp2*, *Ctsd1* and *Cyp1b1* expressions but for the *Lgr4* mutant they only show Pgr and Greb1 (Supplementary Figure 4C). The authors should also check *Wisp2*, *Ctsd1* and *Cyp1b1* expressions in *Lgr4* mutant, to test if these markers show the same trend of Rspo1 cKO, to better demonstrate that Rspo1 and *Lgr4* cooperates for regulating *Esr1* transcription.

2\) Figure 4: The authors should perform a western blot or immunofluorescence of ERα in *Lgr4* lof cells, as they did with Rspo1 cKO (4i,g).

Reviewer \#2:

Dr. Zeng\'s group previously reported that estrogen and progesterone signaling could activate RSPO1 and that RSPO1 and *Wnt4* synergize to promote mammary stemness. In this manuscript, the authors studied the effect of RSPO1 on modulating *Esr1* transcription and ERα signaling. They observed that RSPO1 can induce *Esr1* expression in cultured mammary cells, and went on to show that RSPO1 affects *Esr1* expression in mammary cells through LGR4-cAMP-PKA-CREB but independent of Wnt signaling. Demonstrating a Wnt signaling-independent effect on *Esr1* transaction is significant as RSPO1 is primarily known to bind LGR4/5/6 to potentiate Wnt signaling. However, LGR4 has been reported previously to activate *Esr1* in non-mammary cells and via cAMP-PKA-CREB cells as cited in the Discussion. Furthermore, this work is largely preliminary based on cultures of cells isolated from mice and primarily one single mouse cell line Eph4. The direct in vivo evidence is weak. Therefore, while it is important to study how RSPO1 regulates *Esr1* in mammary cells, this manuscript did not make a significant further advance beyond what is already published. Main concerns are listed below:

1\) The in vivo evidence that RSPO1 regulates *Esr1* expression in mammary cells is weak. The authors generated a Rspo1 conditional KO mouse line. In comparing the *Esr1* expression between WT and KO mice, the authors showed a tangential cut of a duct rather than a typical duct with lumen (Figure 4G), and they failed to quantify and compare these immunofluorescence-stained ducts. Such quantification would have provided much needed in vivo evidence. Instead, the authors chose to isolate a subset of mammary cells for qPCR for ERα transcriptional targets and ERα Western blotting. However, RSPO1 may have changed the cell fate, and the isolated cells from the KO mice could be a skewed subset, unsuitable for comparison with the WT cell preparations. Furthermore, the ERα Western lacked statistical consideration, and *Esr1* qPCR was not performed.

2\) To support their claim that RSPO1 regulates *Esr1* independent of Wnt signaling, they presented in vitro data (Figure 3) that suppressing Wnt signaling could not dampen RSPO1 effects on *Esr1* expression while activating Wnt signaling suppressed *Esr1* expression. Next, they generated a tamoxifen induced knockout line of *Wnt4* (Figure 5). It is bewildering that the authors did not carefully examine the ER expression in the mammary glands from these mice. Rather they only performed qPCR analysis of a subset of mammary cells isolated from conditional *Wnt4* KO mice, which suffers the same flaw as above. The qPCR indeed showed decreased *Esr1* expression, but the Figure 5 legend states that \"Loss of *Wnt4* does not affect *Esr1* expression in luminal cells,\" leading this reviewer to wonder what exactly the authors attempted to prove. Furthermore, any observation of knockout of a single member of the large Wnt gene family on *Esr1* expression cannot be extrapolated to support the claim that RSPO1 activation of *Esr1* expression does not require Wnt signaling. In addition, it is a huge stretch to cite Lindley et al., 2015 to claim that Wnt/catenin has been reported to suppress ER when the cited paper only showed LBH can regulate ER. LBH is one of the hundreds of target genes that may be regulated by Wnt signaling in various contexts. Not every function of these huge family of target genes can be extrapolated as Wnt signaling effects.

3\) In addition to RSPO1-N137Q in Figure 6F, the authors should test other RSPO1 mutants in inducing *Esr1* expression, including RSPO1 F110A/F106A (which could not bind to LGR4) and RSPO1 R66A/Q71A (which could bind to LGR4 but could not amplify Wnt signaling). These experiments are important as positive data would provide direct evidence that LGR4 but not activation of Wnt/β-catenin signaling is required for RSPO1 in inducing *Esr1* expression.

4\) The authors presented evidence that RSPO1 can modulate cAMP-PKA-CREB to transactivate *Esr1*; however, the authors cannot make the jump that RSPO1 does this via LGR4 and independent of Wnt signaling. These authors did not test in their own cell lines whether LGR4 is required for this RSPO1 regulation of cAMP-PKA-CREB and whether the G protein activities of LGR4 are involved in *Esr1* expression.

5\) While it is reasonable to isolate ERα positive mammary cells for testing the effect of RSPO1, the data would have been much more convincing if they also included ERα-negative cells as a control and showed no induction of ERα. The authors also did not explain why RSPO1 needs to act by a paracrine manner to activate LGR4 to activate *Esr1* expression. What prevents RSPO1 from activating LGR4 on the RSPO1-producing cells?

6\) Only one shRNA against LGR4 is used. It is uncertain that the observed effects on *Esr1* are not due to off-target targets. This is especially grave in Figure 2E which shows that this LGR4 shRNA can suppress *Esr1* in MCF7 cells, which has been reported to have very low levels of LGR4.

7\) It is unclear whether RSPO1 affects Wnt signaling in their experiment models. In Figure 3A, RSPO1 treatment of mammary cells in vitro did not affect *Axin2* mRNA levels. However, in Figure 3C, RSPO1 alone significantly enhanced *Axin2* mRNA levels. There is no explanation for this discrepancy. The authors did not show whether their conditional RSPO1 knockout mice impacted Wnt signaling.

Reviewer \#3:

This is an elegantly performed study demonstrating a novel function of R-spondin1 in regulating estrogen receptor expression independent of Wnt/β-catenin signaling.

I have no concerns.

10.7554/eLife.56434.sa2

Author response

> \[...\] My only main point concerns the major finding that Rspo1 regulates the cAMP-PKA-Esr1 axis via Lgr4. To better support this conclusion, the authors should provide some additional data:
>
> 1\) Figure 4H: For Rspo1 cKO, the authors show Pgr, Wisp2, Ctsd1 and Cyp1b1 expressions but for the Lgr4 mutant they only show Pgr and Greb1 (Supplementary Figure 4C). The authors should also check Wisp2, Ctsd1 and Cyp1b1 expressions in Lgr4 mutant, to test if these markers show the same trend of Rspo1 cKO, to better demonstrate that Rspo1 and Lgr4 cooperates for regulating Esr1 transcription.

Following the reviewer's suggestion, we performed qPCR analysis for *Wisp2, Ctsd1* and *Cyp1b1* and have included the data into revised Figure 4---figure supplement 2E. Consistent with the decrease seen in Rspo1-cKO, expression of *Wisp2* and *Ctsd1* also reduced in *Lgr4* mutant. We did not included *Cyp1b1*, as its expression level was very low, therefore its change may not be a proper indication of ERα signaling activities. For similar reason, we also removed *Cyp1b1* data from revised Figure 4K.

> 2\) Figure 4: The authors should perform a western blot or immunofluorescence of ERα in Lgr4 lof cells, as they did with Rspo1 cKO (Figure 4G, I).

Following the suggestion, we performed immunofluorescent staining of ERα in control (*Lgr4^+/-^*) and *Lgr4^-/-^* mutant mammary sections (revised Figure 4---figure supplement 2C, D). As expected, the proportion of ERα+ luminal cell was decreased in *Lgr4^-/-^*, in line with the decrease seen in Rspo1-cKO.

> Reviewer \#2:
>
> Dr. Zeng\'s group previously reported that estrogen and progesterone signaling could activate RSPO1 and that RSPO1 and Wnt4 synergize to promote mammary stemness. In this manuscript, the authors studied the effect of RSPO1 on modulating Esr1 transcription and ERα signaling. They observed that RSPO1 can induce Esr1 expression in cultured mammary cells, and went on to show that RSPO1 affects Esr1 expression in mammary cells through LGR4-cAMP-PKA-CREB but independent of Wnt signaling. Demonstrating a Wnt signaling-independent effect on Esr1 transaction is significant as RSPO1 is primarily known to bind LGR4/5/6 to potentiate Wnt signaling. However, LGR4 has been reported previously to activate Esr1 in non-mammary cells and via cAMP-PKA-CREB cells as cited in the Discussion. Furthermore, this work is largely preliminary based on cultures of cells isolated from mice and primarily one single mouse cell line Eph4. The direct in vivo evidence is weak. Therefore, while it is important to study how RSPO1 regulates Esr1 in mammary cells, this manuscript did not make a significant further advance beyond what is already published. Main concerns are listed below:
>
> 1\) The in vivo evidence that RSPO1 regulates Esr1 expression in mammary cells is weak. The authors generated a Rspo1 conditional KO mouse line. In comparing the Esr1 expression between WT and KO mice, the authors showed a tangential cut of a duct rather than a typical duct with lumen (Figure 4G), and they failed to quantify and compare these immunofluorescence-stained ducts. Such quantification would have provided much needed in vivo evidence. Instead, the authors chose to isolate a subset of mammary cells for qPCR for ERα transcriptional targets and ERα Western blotting. However, RSPO1 may have changed the cell fate, and the isolated cells from the KO mice could be a skewed subset, unsuitable for comparison with the WT cell preparations. Furthermore, the ERα Western lacked statistical consideration, and Esr1 qPCR was not performed.

We respectfully disagree with the reviewer. The wholemount immunostaining shown in Figure 4G (the reviewer referred as \"a tangible cut\") provides a broader view compared to the traditional cross section. In our opinion, whole mount immunostaining is a technical advance that better demonstrates the distribution/density of ERα+ cells along the mammary duct, which cross section fails to achieve. Following the suggestion, we included quantification data showing that decreased percentage of ERα+ cells (revised Figure 4H).

I hope the reviewer agrees that, based on the above observation, performing qPCR or WB using total luminal cells would merely confirm the decreased percentage of ERα+ cells, instead of providing further information.

In our opinion, the above quantification likely reflects the overall reduction of ERα level in luminal compartment. Although we could not exclude the possible switching of ER+ to ER- cell fate due to other indirect reasons, we tested a more direct possibility---whether it is the reduction of ERα expression in ER+ compartment that results in loss of ER+ cells. To this end, we isolated ER+ luminal cells (Lin^-^, CD24^+^, CD29^lo^, Sca1^+^), and analyzed ERα levels as well as ERα signaling activities. We were able to show that on top of decreased percentage of ERα+ cells, the remaining ERα+ cells also displayed reduced ERα level and compromised ERα signaling activities (Figure 4I-K). The loss of ERα+ cells (Figure 4G-H) and the reduction in ERα level in the remaining ERα+ cells (Figure 4J) likely reflect different extents of Rspo1 regulation over ERα+ expression.

Following the suggestion, we have included the qPCR analysis of *Esr1* (revised Figure 4I).

> 2\) To support their claim that RSPO1 regulates Esr1 independent of Wnt signaling, they presented in vitro data (Figure 3) that suppressing Wnt signaling could not dampen RSPO1 effects on Esr1 expression while activating Wnt signaling suppressed Esr1 expression. Next, they generated a tamoxifen induced knockout line of Wnt4 (Figure 5). It is bewildering that the authors did not carefully examine the ER expression in the mammary glands from these mice. Rather they only performed qPCR analysis of a subset of mammary cells isolated from conditional Wnt4 KO mice, which suffers the same flaw as above. The qPCR indeed showed decreased Esr1 expression, but the Figure 5 legend states that \"Loss of Wnt4 does not affect Esr1 expression in luminal cells,\" leading this reviewer to wonder what exactly the authors attempted to prove. Furthermore, any observation of knockout of a single member of the large Wnt gene family on Esr1 expression cannot be extrapolated to support the claim that RSPO1 activation of Esr1 expression does not require Wnt signaling. In addition, it is a huge stretch to cite Lindley et al., 2015 to claim that Wnt/catenin has been reported to suppress ER when the cited paper only showed LBH can regulate ER. LBH is one of the hundreds of target genes that may be regulated by Wnt signaling in various contexts. Not every function of these huge family of target genes can be extrapolated as Wnt signaling effects.

We respectfully disagree with the reviewers. As explained above, using isolated ER+ luminal cells to examine ER signaling is a more stringent experimental design in our opinion. But we understand the reviewer's concern, thus we also performed qPCR using whole luminal cells from control and *Wnt4*-cKO mice, which confirmed that loss of *Wnt4* increases *Esr1* expression and ER signaling activities (see [Author response image 1](#respfig1){ref-type="fig"}).

![](elife-56434-resp-fig1){#respfig1}

Our apologies that the title in Figure 5 caused confusion. We have modified it to "Loss of *Wnt4* increases *Esr1* expression in luminal cells".We respectfully disagree with the reviewers regarding the issue of overstatement when describing the effect of *Wnt4*. In Figure 3, when we concluded that "*Esr1* expression induced by Rspo1 is independent of Wnt/β-catenin signaling", aside from *Wnt4*, we used activators Wnt3a and CHIR, and inhibitors FzCRD and XAV939. Those results collectively supported our conclusion. Subsequently, in Figure 5, we used *Wnt4*-cKO as a genetic model for in vivo validation, considering that *Wnt4* is the major Wnt member in adult mammary epithelium, and that *Wnt4*/Rspo1 synergy has been reported in the mammary gland. In our opinion, our subtitle, "Genetic evidence supports that *Esr1* regulation is independent of luminal *Wnt4*" was precise, and did not extend to refer other Wnt/β-catenin signaling.

Regarding how to cite the Lindley et al., 2015 paper, it has been rephrased to "...consistent with the previous report, in which Wnt-controlled transcriptional regulator LBH repress luminal genes, mainly *Esr1* (Lindley et al., 2015)." Of note, "Wnt-controlled transcriptional regulator LBH" is the exact word used in the title of Lindley et al., 2015.

> 3\) In addition to RSPO1-N137Q in Figure 6F, the authors should test other RSPO1 mutants in inducing Esr1 expression, including RSPO1 F110A/F106A (which could not bind to LGR4) and RSPO1 R66A/Q71A (which could bind to LGR4 but could not amplify Wnt signaling). These experiments are important as positive data would provide direct evidence that LGR4 but not activation of Wnt/β-catenin signaling is required for RSPO1 in inducing Esr1 expression.

We thank the reviewer for the suggestion, and performed the experiments accordingly. As shown in revised Figure 6F, both RSPO1-N137Q mutant (prevents RSPO1 secretion) and RSPO1-F110A/F106A mutant (unable to bind to LGR4) abolished RSPO1\'s ability to activate *Esr1* luciferase reporter, while treatment with RSPO1-R66A/Q71A mutant (could not amplify Wnt signaling) showed similar *Esr1* luciferase activation as treatment with wildtype RSPO1. These results further supported that Wnt/β-catenin signaling is not required for *Esr1*-induction by Rspo1.

> 4\) The authors presented evidence that RSPO1 can modulate cAMP-PKA-CREB to transactivate Esr1; however, the authors cannot make the jump that RSPO1 does this via LGR4 and independent of Wnt signaling. These authors did not test in their own cell lines whether LGR4 is required for this RSPO1 regulation of cAMP-PKA-CREB and whether the G protein activities of LGR4 are involved in Esr1 expression.

We apologize for the confusion caused. The requirement for *Lgr4* in Rspo1 induced *Esr1* expression has been shown in primary luminal cells (Figure 2D) and in T47D cells (Figure 2E). The connection of Rspo1 to cAMP-PKA-CREB-*Esr1* is revealed in Figure 6 as the reviewer pointed out. The connection of *Lgr4* to cAMP-PKA is known^1-3^. Together, in our opinion, it is logical to propose such a signaling model.

> 5\) While it is reasonable to isolate ERα positive mammary cells for testing the effect of RSPO1, the data would have been much more convincing if they also included ERα-negative cells as a control and showed no induction of ERα. The authors also did not explain why RSPO1 needs to act by a paracrine manner to activate LGR4 to activate Esr1 expression. What prevents RSPO1 from activating LGR4 on the RSPO1-producing cells?

We thank the reviewer for the suggestion. We isolated ER- luminal cells and cultured them in the presence of RSPO1 for 2 days. Treatment of RSPO1 to ER- luminal cells didn't result in significant change in *Esr1* expression. We have included this result in revised Figure 1---figure supplement 1C.

The reviewer raised an interesting point. At this stage, we don't know what prevents Rspo1 from acting on ER- cells. It could be the intrinsic mechanism of ER- cells, which is a subject of future study.

> 6\) Only one shRNA against LGR4 is used. It is uncertain that the observed effects on Esr1 are not due to off-target targets. This is especially grave in Figure 2E which shows that this LGR4 shRNA can suppress Esr1 in MCF7 cells, which has been reported to have very low levels of LGR4.

Following the suggestions, we generated one additional shRNA and replaced MCF7 cells with T47D cells that have higher LGR4 expression. We confirmed that both shRNAs (sh1 and sh2) are efficient in reducing endogenous *LGR4* expression in T47D cells (revised Figure 2---figure supplement 1), and produce consistent results in eliminating RSPO1 induced *Esr1*-luciferase reporter activities (Revised Figure 2E).

> 7\) It is unclear whether RSPO1 affects Wnt signaling in their experiment models. In Figure 3A, RSPO1 treatment of mammary cells in vitro did not affect Axin2 mRNA levels. However, in Figure 3C, RSPO1 alone significantly enhanced Axin2 mRNA levels. There is no explanation for this discrepancy. The authors did not show whether their conditional RSPO1 knockout mice impacted Wnt signaling.

We apologize for the confusion caused. We have incorporated more repeats in revised Figure 3C, and our combined dataset suggest there is no significant change in *Axin2* expression after RSPO1 treatments.

Our RSPO1-cKO indeed resulted in decreased Wnt signaling activities in basal cells (see [Author response image 2](#respfig2){ref-type="fig"}). Control and RSPO1-cKO mice were administered with tamoxifen at 8-week-old and mammary glands were harvested after 4 weeks. Basal cells were isolated for qPCR analysis. We found that the expressions of Wnt target genes, *Axin2* and *Lgr5*, are reduced.

![](elife-56434-resp-fig2){#respfig2}
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